BLOOD-BASED BIOMARKERS FOR PREDICTING POST-STROKE PROGNOSIS: A SCOPING REVIEW OF PENTRAXIN-3, NEUROPENTRAXIN-1, AND NEUROPENTRAXIN-2
DOI:
https://doi.org/10.20961/magnaneurologica.v4i2.3308Keywords:
blood-based biomarker, neuropentraxin 1, neuropentraxin 2, pentraxin 3, strokeAbstract
Background: Stroke remains a major global health challenge, with substantial losses in disability-adjusted life-years, particularly in low-middle-income countries. Predicting post-stroke outcomes remains challenging because outcomes are driven by complex and overlapping processes, including inflammation, vascular injury, and neurodegeneration. Consequently, blood-based biomarkers, such as the pentraxin group that reflect underlying pathophysiology, have gained attention. However, existing evidence is fragmented and heterogeneous, underscoring the need for systematic mapping of the pentraxin group as biologically informed prognostic tools.
Objective: This systematic scoping review aims to map and synthesize existing evidence on the prognostic value of blood-based biomarkers Pentraxin-3 (PTX3), Neuropentraxin-1 (NPTX1), and Neuropentraxin-2 (NPTX2) in predicting clinical outcomes after stroke.
Methods: This PRISMA-ScR–guided scoping review systematically mapped evidence on blood-based biomarkers: PTX3, NPTX1, and NPTX2, for post-stroke prognosis from 6 databases and used NOS for quality assessment.
Results: A total of 18 studies were included in the final scoping review. Lower serum NPTX2 levels were significantly associated with post-stroke cognitive impairment. Studies investigating PTX3 demonstrated substantial heterogeneity in sampling timing, cutoff definitions, and follow-up duration. Across studies, higher PTX3 concentrations were independently associated with increased mortality (AUC ~0.73–0.81, P value <0.0001), greater baseline neurological severity as measured by the National Institutes of Health Stroke Scale (NIHSS), and poorer functional outcomes assessed by the modified Rankin Scale (mRS).
Conclusion: Despite the large heterogeneity of studies, the overall evidence supports PTX3, NPTX1, and NPTX2 as less-invasive prognostic blood-based biomarkers for post-stroke outcomes. However, studies on NPTX1 and NPTX2 are still very limited.
References
1. World Stroke Organization. Impact of Stroke. Retrieved on January 10, 2026. Available from: https://www.world-stroke.org/world-stroke-daycampaign/about-stroke/impact-of-stroke?
2. Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World Stroke Organization: Global Stroke Fact Sheet 2025. Int J Stroke; 2025. 20(2):132–44. DOI: 10.1177/17474930241308142
3. Xiao L, Huang Y, Wu L, Zeng S, Qiu C, Li X, et al. The role of inflammation in ischemic stroke: from biomarker to treatment. Front Immunol; 2025. 16:1608353. DOI: 10.3389/fimmu.2025.1608353
4. Zhang Y, Hu H, Liu C, Wu J, Zhou S, Zhao T, et al. Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis. Brain Behav; 2021. DOI: 10.1002/brb3.1956
5. Zhu Y, Fan K, Zhao X, Hou K. The Association Between Serum Pentraxin-3 Level at Admission and the Functional Outcome of Patients After Acute Ischemic Stroke: A Meta-Analysis. Balkan Med J; 2025. 42(3):201–11. DOI: 10.4274/balkanmedj.galenos.2025.2025-1-36
6. Wu Y, Luo R, Guan H, Zhang X, Yang X, Wang W, et al. Neuronal pentraxin 1 accelerates post-stroke atherosclerosis by inducing endothelial cell senescence. Int Immunopharmacol; 2025. 164:115363. DOI: 10.1016/j.intimp.2025.115363
7. Gomez De San Jose N, Massa F, Halbgebauer S, Oeckl P, Steinacker P, Otto M. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm; 2022. 129(2):207–30. DOI: 10.1007/s00702-021-02411-2
8. Peng H, Zhang L, Tang Y, Huang P, Luo S, She Z, et al. Exploring PTX3: a promising diagnostic marker and therapeutic target in neurology. Gene; 2025. 969:149724. DOI: 10.1016/j.gene.2025.149724
9. Cao Z, Guo X, Ding M, Chen Z, Wang L, Fang Q. Serum pentraxin-3 and plaque burden predict unexplained early neurological deterioration in branch atheromatous disease. World Neurosurg X; 2025. 28:100530. DOI: 10.1016/j.wnsx.2025.100530
10. Hervella P, Alonso-Alonso ML, Sampedro-Viana A, Rodríguez-Yáñez M, López-Dequidt I, Pumar JM, et al. Differential blood-based biomarkers of subcortical and deep brain small vessel disease. Ther Adv Neurol Disord; 2024. 17:17562864241243274. DOI: 10.1177/17562864241243274
11. Lv XN, Li ZQ, Li Q. Blood-Based Biomarkers in Intracerebral Hemorrhage. J Clin Med; 2023. 12(20):6562. DOI: 10.3390/jcm12206562
12. Zhang H, Wang R, Wang Z, Wu W, Zhang N, Zhang L, et al. Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role. Biomed Pharmacother; 2022. 156:113783. DOI: 10.1016/j.biopha.2022.113783
13. Hao PH, Fu C, Ma T, He SM, Jia ZP. Prognostic value of serum pentraxin 3 for intracerebral hemorrhage mortality. J Integr Neurosci; 2021. 20(1):137. DOI: 10.31083/j.jin.2021.01.228
14. Lambert A, Kong X, Ratajczak-Tretel B, Atar D, Russell D. Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study. Cerebrovasc Dis; 2020. 49(1):11–20. DOI: 10.1159/000504529
15. Kouchaki E, Babamohammadi A, Nikoueinejad H, Sehat M. Association of Serum Levels of Pentraxin-3, M-ficolin, and Surfactant Protein A with the Severity of Ischemic Stroke. Iran J Allergy Asthma Immunol; 2017. 16(2):140–6. PMID: 28601054
16. Qin LZ, Li W, Huang Y, Lu F, Li SJ, Yang HQ, et al. PTX3 expression in the plasma of elderly ACI patients and its relationship with severity and prognosis of the disease. Eur Rev Med Pharmacol Sci; 2016. 20(19):4112–8. PMID: 27775787
17. Ceylan M, Yalcin A, Bayraktutan OF, Atis O, Acar E. Serum pentraxin-3 levels in acute stroke: No association with stroke prognosis. Atherosclerosis; 2015. 243(2):616–20. DOI: 10.1016/j.atherosclerosis.2015.10.089
18. Sezer S, Uçar F, Ulusoy EK, Erdoğan S, Bilen Ş, Züngün C, et al. Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers? Turk J Med Sci; 2014. 44:16–23. DOI: 10.3906/sag-1211-90
19. Ryu WS, Kim CK, Kim BJ, Kim C, Lee SH, Yoon BW. Pentraxin 3: A novel and independent prognostic marker in ischemic stroke. Atherosclerosis; 2012. 220(2):581–6. DOI: 10.1016/j.atherosclerosis.2011.11.036
20. Zhang CY, Han HD, Wang SY, Huang SR, Deng BQ. Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis. Med Sci Monit; 2018. 24:4427–32. DOI: 10.12659/MSM.909015
21. Jiang F, Li J, Yu S, Miao J, Wang W, Xi X. Body fluids biomarkers associated with prognosis of acute ischemic stroke: progress and prospects. Future Sci OA; 2024. 10(1):FSO931. DOI: 10.2144/fsoa-2023-0142
22. Li J, Ma W, Gu S. Exploring the Relationship Between Serum Neuronal Pentraxin 2 and Poststroke Cognitive Impairment in Patients With First-Episode Acute Ischemic Stroke. Brain Behav; 2025. 15(2):e70305. DOI: 10.1002/brb3.70305
23. Chapman G, Shanmugalingam U, Smith PD. The Role of Neuronal Pentraxin 2 (NP2) in Regulating Glutamatergic Signaling and Neuropathology. Front Cell Neurosci; 2020. 13:575. DOI: 10.3389/fncel.2019.00575
24. Gualdi-Russo E, Zaccagni L. The Newcastle–Ottawa Scale for Assessing the Quality of Studies in Systematic Reviews. Publications; 2026. 14(1):4. DOI: 10.3390/publications14010004
25. Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair and Cancer. Physiol Rev; 2018. 98(2):623–39. DOI: 10.1152/physrev.00016.2017
26. Shindo A, Maki T, Mandeville ET, Liang AC, Egawa N, Itoh K, et al. Astrocyte-Derived Pentraxin 3 Supports Blood–Brain Barrier Integrity Under Acute Phase of Stroke. Stroke; 2016. 47(4):1094–100. DOI: 10.1161/STROKEAHA.115.012133
27. Carrizzo A, Lenzi P, Procaccini C, Damato A, Biagioni F, Ambrosio M, et al. Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway. Circulation; 2015. 131(17):1495–505. DOI: 10.1161/CIRCULATIONAHA.114.014822
28. Lee YT, Gong M, Chau A, et al. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis. J Infect; 2018. 76(1):1–10. DOI: 10.1016/j.jinf.2017.10.016
29. Wang DL, Jiao F, Jiang YL, Song HD, Li B, Gao Q, et al. Pentraxin 3 as a Prognostic Biomarker in Aneurysmal Subarachnoid Hemorrhage. Med Sci Monit; 2025. DOI: 10.12659/MSM.947133
30. Ristagno G, Fumagalli F, Bottazzi B, Mantovani A, Olivari D, Novelli D, Latini R. Pentraxin 3 in Cardiovascular Disease. Front Immunol; 2019. 17(10):823. DOI: 10.3389/fimmu.2019.00823
31. Zhang Z, Chen X, Sheng Z, Jiang N, Zou WQ. Cerebrospinal fluid neuronal pentraxin levels are associated with tau pathology via microglia–astrocyte signaling in Alzheimer’s disease. J Neuroinflammation; 2025. 22(1):221. DOI: 10.1186/s12974-025-03545-w
32. Iordache MP, Buliman A, Costea-Firan C, Gligore TCI, Cazacu IS, Stoian M, et al. Immunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement. Int J Mol Sci; 2025. 26(16):7928. DOI: 10.3390/ijms26167928
33. Bustamante A, Simats A, Vilar-Bergua A, García-Berrocoso T, Montaner J. Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. Neurotherapeutics; 2016. 13(4):671–84. DOI: 10.1007/s13311-016-0470-2
34. Van Der Ende EL, Meeter LH, Xie Y, Panman JL, Poos JM, Jiskoot LC, et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry; 2020. 91(6):612–21. DOI: 10.1136/jnnp-2019-322493
35. Zhou J, Wade SD, Graykowski D, Xiao MF, Zhao B, Giannini LAA, et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci Transl Med; 2023. 15(689):eadf0141. DOI: 10.1126/scitranslmed.adf0141
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Elizabeth Divina, Siti Alyaa Salma Ghozali, Pukovisa Prawiroharjo
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
